Please try another search
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Name | Age | Since | Title |
---|---|---|---|
Robert Jay Spiegel | 73 | 2010 | Independent Director |
V. Bryan Lawlis | 71 | 2012 | Independent Director |
Susan M. Molineaux | 68 | 2012 | Independent Director |
John A. Scarlett | 71 | 2011 | Chairman of the Board, President & CEO |
John F. McDonald | 62 | 2022 | Independent Director |
Elizabeth G. O'Farrell | 58 | 2019 | Lead Independent Director |
Dawn Carter Bir | 53 | 2019 | Independent Director |
Gaurav Aggarwal | 51 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review